In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $6.77 in the prior trading day, Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) closed at $6.41, down -5.32%. In other words, the price has decreased by -$5.32 from its previous closing price. On the day, 4.1 million shares were traded. BCRX stock price reached its highest trading level at $6.57 during the session, while it also had its lowest trading level at $6.015.
Ratios:
Our goal is to gain a better understanding of BCRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.58 and its Current Ratio is at 2.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on February 25, 2025, initiated with a Outperform rating and assigned the stock a target price of $15.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on September 18, 2023, whereas the target price for the stock was revised from $9 to $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 13 ’24 when Hutson Nancy J sold 7,000 shares for $7.54 per share. The transaction valued at 52,780 led to the insider holds 86,638 shares of the business.
Hutson Nancy J bought 7,000 shares of BCRX for $52,584 on Dec 13 ’24. On Jun 24 ’24, another insider, McKee Amy E, who serves as the Director of the company, sold 8,600 shares for $6.32 each. As a result, the insider received 54,352 and left with 27,831 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1339433600 and an Enterprise Value of 1947764992. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.97. Its current Enterprise Value per Revenue stands at 4.322 whereas that against EBITDA is 1123.927.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.13, which has changed by 0.34381557 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $9.50, while it has fallen to a 52-week low of $4.03. The 50-Day Moving Average of the stock is -19.99%, while the 200-Day Moving Average is calculated to be -16.54%.
Shares Statistics:
The stock has traded on average 3.36M shares per day over the past 3-months and 3120410 shares per day over the last 10 days, according to various share statistics. A total of 208.54M shares are outstanding, with a floating share count of 197.24M. Insiders hold about 5.61% of the company’s shares, while institutions hold 78.47% stake in the company. Shares short for BCRX as of 1741910400 were 19774241 with a Short Ratio of 6.17, compared to 1739491200 on 16675736. Therefore, it implies a Short% of Shares Outstanding of 19774241 and a Short% of Float of 9.54.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
